Auris Medical to Provide Business Update on AM-301 Program on Tuesday, April 13, 2021
April 08 2021 - 8:00AM
Hamilton, Bermuda, April 8, 2021 – Auris Medical Holding Ltd.
(NASDAQ: EARS), a clinical-stage company dedicated to developing
therapeutics that address important unmet medical needs in
neurotology, rhinology and allergy and CNS disorders, today
announced that it will provide a business update on its AM-301
program for protection against airborne viruses and allergens on
Tuesday, April 13, 2021. Following the announcement, Auris
Medical's management team will host a live conference call and
webcast at 8:00 am Eastern Time (2:00 pm Central European
Time).
To participate in this conference call, dial
+1-877-870-9135 (US, toll free) or +44-2071-928-338
(international), and enter passcode 5649276. A live webcast of the
conference call can be accessed in the Investor Relations section
of the Auris Medical website at www.aurismedical.com. A replay will
be available approximately two hours following the live call.
About Auris Medical
Auris Medical is a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in neurotology, rhinology and allergy and CNS
disorders. The Company is focused on the development of intranasal
betahistine for the treatment of vertigo (AM-125, in Phase 2) and
for the prevention of antipsychotic-induced weight gain and
somnolence (AM-201, post Phase 1b). Through its affiliate Altamira
Medica, the Company is developing a nasal spray for protection
against airborne viruses and allergens (AM-301). In addition, Auris
Medical has two Phase 3 programs under development: Sonsuvi®
(AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101)
for acute inner ear tinnitus. The Company was founded in 2003 and
is headquartered in Hamilton, Bermuda with its main operations in
Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade
on the NASDAQ Capital Market under the symbol “EARS.”
Investor contact:
investors@aurismedical.com
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Apr 2023 to Apr 2024
